Home > Press > Scottish Medicines Consortium Accepts ABRAXANE® for Use within National Health Service for Scotland
Abstract:
Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
Scottish Medicines Consortium Accepts ABRAXANE® for Use within National Health Service for Scotland
Los Angeles, CA | Posted on April 13th, 2010
"ABRAXANE's acceptance by the SMC is a significant milestone in our goal to provide patients in the United Kingdom and across Europe with an innovative treatment option," said Jean-François Gimonet, M.D., Vice President, European Operations of Abraxis BioScience.
For further information on the SMC's decision, please visit www.scottishmedicines.org.uk
####
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s product pipeline is based on a proprietary tumor targeting technology known as the nab® (nanoparticle albumin bound) platform. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
For more information, please click here
Contacts:
Investors and Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
+1 310-883-1300
Media Inquiries
Zeno Group
Victoria Fort
+1 202-361-0445
Copyright © Abraxis BioScience
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Announcements
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Nanobiotechnology
Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013
Shape of nanoparticles points the way toward more targeted drugs: A collaboration of scientists at Sanford-Burnham and the University of California, Santa Barbara, finds that rod-shaped particles, rather than spherical particles, appear more effective at adhering to cells June 10th, 2013
Catching individual molecules in a million with optical antennas inside nano-boxes June 10th, 2013
Whispering light hears liquids talk: University of Illinois researchers build first-ever bridge between optomechanics and microfluidics June 7th, 2013